ANN ARBOR, Mich.--(BUSINESS WIRE)--AlphaCore Pharma, a biopharmaceutical company developing ACP-501 (rhLCAT) for the treatment of high risk atherosclerosis and serious lipid metabolism disorders, today announced it has received orphan drug designation from the European Medicines Agency (EMA) for ACP-501 for the treatment of familial LCAT deficiency (FLD). This EMA designation follows an earlier FLD orphan drug designation granted by the US Food and Drug Administration.
